Search ARM

In the News



Nov
25
2021

Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies

Scrip

The Alliance for Regenerative Medicine reported on 22 November that cell and gene therapy companies have raised enough money already in 2021 to break the record set in 2020. Venture capital financings are driving the surge with $8.2bn raised through the third quarter, which is up 45% from the same nine-month period last year.

Nov
12
2021

Califf’s Return as FDA Head Will Give Drug Competition a Boost

Bloomberg Law

Improving drug competition and boosting patient access to innovative treatments will likely be among the priorities of Robert Califf at the helm of the Food and Drug Administration, policy analysts say.

Nov
11
2021

CBER Designing Triage System For Gene Therapy Submissions In Lieu Of ‘First In, First Out’ System

Pink Sheet

Cell and gene therapy sponsors could see some submissions gain attention at the US Food and Drug Administration sooner that those already on file if they are deemed more important to the development program. Center for Biologics Evaluation and Research Director Peter Marks said staff are working on a triage process for some submissions, apparently so product development does not slow unnecessarily.

Nov
10
2021

Industry calls for technical, scope changes in ICH S12 guideline

Regulatory Focus

In response to the US Food and Drug Administration’s (FDA) consultation on the International Council for Harmonisation’s (ICH) S12 guideline on nonclinical biodistribution considerations for gene therapy products, two industry groups and drugmaker Novartis have suggested changes to the document.

Oct
29
2021

Bespoke Gene Therapy Consortium created to collaborate in development of rare disease gene therapies

PMLiVE

While there are more than 7,000 rare diseases, only two gene therapies have been approved by the US Food and Drug Administration (FDA) to treat inheritable conditions. The Bespoke Gene Therapy Consortium (BGTC) aims to change that.

Oct
28
2021

NIH, FDA spearhead broad partnership to speed gene therapy research

Biopharma Dive

The National Institutes of Health and Food and Drug Administration are banding together with drugmakers and nonprofits to speed the development of gene therapies for rare diseases. The group is launching the Bespoke Gene Therapy Consortium, with planned funding of $76 million over five years.

Oct
28
2021

Pfizer, Novartis sign on to accelerate gene therapies for rare diseases with US agencies

Fierce Biotech

A cadre of big and small biotechs and pharmas, plus nonprofit organizations, have signed on to a new U.S. initiative to go after gene therapies for rare diseases. Called the Bespoke Gene Therapy Consortium, or BGTC, the initiative is headed up by the FDA and the National Institutes of Health (NIH) and is designed to accelerate development of gene therapies. The agencies are putting up $76 million over five years.

Oct
27
2021

Public-private partnership launched to accelerate gene therapies for rare diseases

STAT News

The National Institutes of Health and U.S. Food and Drug Administration unveiled a public-private partnership Wednesday aimed at accelerating gene therapies for the roughly 30 million Americans living with a rare genetic disease.